Safety evaluation of apremilast for the treatment of psoriasis

Psoriasis

Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicenter study by the Spanish Psoriasis Group

J Eur Acad Dermatol Venereol.

Del Alcázar E, Suárez-Pérez JA, Armesto S, Rivera R, Herrera-Acosta E, Herranz P, Martín I, Montesinos E, Hospital M, Vilarrasa E, Ferran M, Ruiz-Villaverde R, Sahuquillo-Torralba A, Ruiz-Genao DP, Pérez-Barri S, Muñoz C, Llamas M, Valentí F, Josune Mitxelena M, López-Ferrer A, Carretero G, Vidal D, Mollet J, Belinchón I, Manuel Carrascosa J

doi: 10.1111/jdv.16439.

Psoriasis

Calcipotriol plus betamethasone dipropionate aerosol foam versus apremilast, methotrexate, acitretin, or fumaric acid esters for the treatment of plaque psoriasis: A matching-adjusted indirect comparison

J Eur Acad Dermatol Venereol.

Bewley A, Shear NH, Calzavara-Pinton PG, Hansen JB, Nyeland ME, Signorovitch J

doi: 10.1111/jdv.15369.

Psoriasis

Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus

J Am Acad Dermatol.

Rigopoulos D, Baran R, Chiheb S, Daniel CR 3rd, Di Chiacchio N, Gregoriou S, Grover C, Haneke E, Iorizzo M, Pasch M, Piraccini BM, Rich P, Richert B, Rompoti N, Rubin AI, Singal A, Starace M, Tosti A, Triantafyllopoulou I, Zaiac M

doi: 10.1016/j.jaad.2019.01.072.

PsoriasisPsoriatic Arthritis

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials

J Eur Acad Dermatol Venereol.

Thaçi D, Kimball A, Foley P, Poulin Y, Levi E, Chen R, Feldman SR

doi: 10.1111/jdv.13918.

PsoriasisFurther Publications Dermatology

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up

Br J Dermatol

Papp KA, Lebwohl MG, Puig L, Ohtsuki M, Beissert S, Zeng J, Rubant S, Sinvhal R, Zhao Y, Soliman AM, Alperovich G, Leonardi C

doi: 10.1111/bjd.20595

Psoriasis

Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate to Severe Psoriasis up to 3 Years of Treatment: Results from A Double-Blind Extension Study

Br J Dermatol.

Bissonnette R, Luger T, Thaçi D, Toth D, Messina I, You R, Guana A, Fox T, Papavassilis C, Gilloteau I, Mrowietz U

doi: 10.1111/bjd.15706.

Psoriasis

Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study

J Am Acad Dermatol.

Van Voorhees AS, Gold LS, Lebwohl M, Strober B, Lynde C, Tyring S, Cauthen A, Sofen H, Zhang Z, Paris M, Wang Y

doi: 10.1016/j.jaad.2020.01.072.

Psoriasis

Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled Phase 4 trial

Eur J Dermatol

Liu L, Zhang C, Wang J, Chen K, Ding Y, Yan G, Lu Q, Li W, Fang H, Cheng H, Zhang J, He Y, Zhu W, Lu Y, Huang J, Pan W, Li M, Cao S, Li S, Han X, He L, Chen Y, Zheng M

doi: 10.1684/ejd.2020.3876

Psoriasis

Safety of Systemic Agents for the Treatment of Pediatric Psoriasis

JAMA Dermatol.

Bronckers IMGJ, Seyger MMB, West DP, Lara-Corrales I, Tollefson M, Tom WL, Hogeling M, Belazarian L, Zachariae C, Mahé E, Siegfried E, Philipp S, Szalai Z, Vleugels RA, Holland K, Murphy R, Baselga E, Cordoro K, Lambert J, Alexopoulos A, Mrowietz U, Kievit W, Paller AS; Psoriasis Investigator Group (PsIG) of the Pediatric Dermatology Research Alliance and the European Working Group on Pediatric Psoriasis (EWGPP)

doi: 10.1001/

Related content

Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicenter study by the Spanish Psoriasis Group

Calcipotriol plus betamethasone dipropionate aerosol foam versus apremilast, methotrexate, acitretin, or fumaric acid esters for the treatment of plaque psoriasis: A matching-adjusted indirect comparison

Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up

Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate to Severe Psoriasis up to 3 Years of Treatment: Results from A Double-Blind Extension Study

Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study

Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled Phase 4 trial

Safety of Systemic Agents for the Treatment of Pediatric Psoriasis